

Amendments to the Specification:

Please replace the paragraph beginning at page 122, line 24, with the following paragraph:

Within another aspect, the present invention provides methods for enhancing drug delivery to the central nervous system (CNS) of a mammal. The blood/brain barrier is largely impermeable to most neuroactive agents, and delivery of drugs to the brain of a mammal often requires invasive procedures. Using a modulating agent as described herein, however, delivery may be by, for example, systemic administration of a modulating agent-drug-targeting agent combination, injection of a modulating agent (alone or in combination with a drug and/or targeting agent) into the carotid artery or application of a skin patch comprising a modulating agent to the head of the patient. Modulating agents for enhancing drug delivery to the central nervous system include those agents that disrupt functions mediated by OB-cadherin or cadherin-5. Certain preferred modulating agents for use within such methods are relatively small cyclic peptides (*e.g.*, a ring size of 4-10 residues; preferably 5-7 residues). Also preferred are multi-functional modulating agents comprising one or more of an atypical cadherin Trp-containing CAR sequence and an N-cadherin CAR sequence, the putative claudin CAR sequence IYSY (SEQ ID NO: 1312), an occludin CAR sequence LYHY (SEQ ID NO: 1309) and/or a JAM CAR sequence, preferably joined by a linker. Alternatively, a separate modulator of, for example, N-cadherin, claudin, JAM and/or occludin-mediated cell adhesion may be administered in conjunction with the modulating agent(s), either within the same pharmaceutical composition or separately. Modulating agents may further comprise antibodies or Fab fragments directed against CAR sequences of other cell adhesion molecule, such as a CAR sequence from an integrin, a classical cadherin, an N-CAM, a JAM, an occludin, a claudin, *etc.*, as described above, or an analogue of such a sequence. In one embodiment, Fab fragments directed against the N-cadherin CAR sequence FHLRAHAVDINGNQV-NH₂ (SEQ ID NO: 1351) and the occludin CAR sequence: GVNPTAQSSGSLSYGSQIYALCNQFYTPAATGLYVDQYLYHYCV VDPQE (SEQ ID NO: 1352) may also be employed, as can Fab fragments directed against a CAR sequence of other cell adhesion molecules, such as an integrin, a classical cadherin, an N-CAM, a JAM, a claudin, *etc.*, as described above, or an analogue of such a sequence.

Please delete the section of the application entitled "Sequence Listing" immediately after the section entitled "Abstract of the Disclosure" on page 169 and insert the enclosed Sequence Listing therefor.